Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs IDEXX Laboratories, Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.26 (market cap $510.01M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 79.3× GraniteShares 2x Long COIN Daily ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 21,041,836). Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CONL | IDXX | |
|---|---|---|
Market Cap | $510.01M | $40.43B |
Volume | 21,041,836 | 692,164 |
Sector | Leveraged / Inverse | Health |
52-Week High | $41.19 | $766.68 |
52-Week Low | $3.93 | $504.70 |
Typical Hold Time | 15 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.85, down 7.27% in the last session. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators suggest potential oversold conditions. The stock faces significant volatility as a leveraged ETF tracking Coinbase performance. Recent news highlights the fund's gap-up movement in early October 2026, but subsequent coverage emphasizes the risks of leveraged products amid Coinbase's 50% decline.
The outlook remains highly speculative given CONL's leveraged structure and dependence on Coinbase volatility. Investment opportunity exists for tactical traders betting on Coinbase rebounds, but risks include amplified losses, decay from daily resets, and crypto market sensitivity. Long-term investors should approach with caution due to the product's complex risk profile.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
